By what date will there exist a published, peer-reviewed report — generally accepted as true by the mainstream scientific community, not merely claimed by a fringe group — that some credible research group has reanimated a whole mammal after that mammal was brought down to cryogenic temperature (e.g., near or below the glass transition point, such as via liquid-nitrogen-range storage) or to an intermediate deep-hypothermic/subzero temperature storage state?

Status Quo and Recent Milestones As of August 2026, no whole mammal has ever been revived from cryogenic or deep-subzero (≤ -20 °C) storage. The frontier remains firmly at the tissue and organ scale. The most relevant milestone is a March 2026 PNAS paper (German et al.) demonstrating operational long-term potentiation in vitrified adult mouse hippocampal slices and whole mouse brains 3 sources. However, electrophysiology was recorded in slices from a non-living brain, meaning memory survival could not be tested scientificamerican.com. At the organ level, the reference achievement remains the 2023 vitrification, nanowarming, and transplantation of rat kidneys nature.com. While July 2026 research demonstrated whole-mammal suspended animation with intact fear-conditioning in murine neonates supercooled to -6 °C nature.com, this is far warmer than the ≤ -20 °C threshold and did not test pre-procedure memories. Historically, the whole-animal subzero record has barely moved since the 1950s.

Technical Hurdles and Binding Constraints Achieving this milestone requires passing a strict conjunctive technical bar: storage at ≤ -20 °C, simultaneous multi-organ ambulatory recovery, and demonstrated retention of pre-procedure learned behavior, followed by peer review and mainstream acceptance. The binding constraint is integrated whole-body recovery. Bringing an intact organism to ice-avoiding cryoprotectant (CPA) concentrations without lethal systemic toxicity across the brain, heart, liver, and vasculature is an unsolved problem, and volumetric nanowarming is currently near its physical limits for small tissue dimensions. While demonstrating memory via behavioral testing (e.g., a maze or fear conditioning) is technically straightforward once an animal survives, the requirement for mainstream scientific replication and acceptance adds a multi-year lag beyond any initial laboratory success.

Funding and Strategic Roadmaps Current funding and industry roadmaps strongly suggest that clinical organ preservation will precede whole-animal revival. The best-capitalized effort, Until Labs (>$100M), explicitly sequences its technical roadmap to target first-in-human regulatory approval for organ cryopreservation before attempting reversible whole-body cryopreservation in a small mammal with restored behavioral function untillabs.com. Dedicated small-mammal projects like CRYORAT have accelerated, but their recent milestones remain in the near-zero temperature range (-2 °C), far from the target threshold 2 sources. The most plausible near-term path to resolution is a well-funded group achieving high-subzero (-20 to -80 °C) equilibrium whole-rodent preservation, which circumvents the extreme difficulty of full liquid-nitrogen vitrification but still demands major advances in CPA delivery and washout.

Pace of Progress and Tail Risks The timeline anticipates several partially sequential, decade-scale steps to move from brain slices and isolated organs to a fully behaving mammal. Practitioner surveys often exhibit significant optimism bias arxiv.org, pushing realistic median expectations into the 2060s. Furthermore, the long tail extending well past 2100 is substantial. There is a genuine possibility that thermomechanical limits and systemic toxicity prove practically insurmountable for an intact circulating organism, or that the field's incentives remain permanently redirected toward the highly lucrative banking of transplantable organs rather than the suspended animation of whole mammals.